Abstract
Data on pregnancy outcome in alemtuzumab-treated women are scarce and derived from safety reports of clinical trials. We report on seven women with overall eight pregnancies during treatment with alemtuzumab in a real-world setting. All pregnancies occurred within 9 months after alemtuzumab treatment, and two of them within 4 months despite patients being informed on pregnancy prevention. We found one congenital cytomegalovirus infection, one spontaneous abortion, one elective abortion due to extrauterine pregnancy, and five live births without congenital abnormalities or birth defects.
This is a preview of subscription content, log in via an institution to check access.
Data availability
Data will be provided upon reasonable request to the corresponding author.
References
European Medicine Agency Lemtrada: summary of product characteristics. 2017
Abramsky O (1994) Pregnancy and multiple sclerosis. Ann Neurol 36(Suppl):S38–S41. https://doi.org/10.1002/ana.410360712
Coles AJ, Cohen JA, Fox EJ, Giovannoni G, Hartung HP, Havrdova E, Schippling S, Selmaj KW, Traboulsee A, Compston DAS, Margolin DH, Thangavelu K, Chirieac MC, Jody D, Xenopoulos P, Hogan RJ, Panzara MA, Arnold DL, Care MS II, Investigators C (2017) Alemtuzumab CARE-MS II 5-year follow-up: efficacy and safety findings. Neurology 89(11):1117–1126. https://doi.org/10.1212/WNL.0000000000004354
Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Fisher E, Brinar VV, Giovannoni G, Stojanovic M, Ertik BI, Lake SL, Margolin DH, Panzara MA, Compston DA, investigators C-MI (2012) Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 380(9856):1819–1828. https://doi.org/10.1016/S0140-6736(12)61769-3
Coles AJ, Fox E, Vladic A, Gazda SK, Brinar V, Selmaj KW, Skoromets A, Stolyarov I, Bass A, Sullivan H, Margolin DH, Lake SL, Moran S, Palmer J, Smith MS, Compston DA (2012) Alemtuzumab more effective than interferon beta-1a at 5-year follow-up of CAMMS223 clinical trial. Neurology 78(14):1069–1078. https://doi.org/10.1212/WNL.0b013e31824e8ee7
Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA, investigators C-MI (2012) Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 380(9856):1829–1839. https://doi.org/10.1016/S0140-6736(12)61768-1
Havrdova E, Arnold DL, Cohen JA, Hartung HP, Fox EJ, Giovannoni G, Schippling S, Selmaj KW, Traboulsee A, Compston DAS, Margolin DH, Thangavelu K, Rodriguez CE, Jody D, Hogan RJ, Xenopoulos P, Panzara MA, Coles AJ, Care-Ms I, Investigators C (2017) Alemtuzumab CARE-MS I 5-year follow-up: durable efficacy in the absence of continuous MS therapy. Neurology 89(11):1107–1116. https://doi.org/10.1212/WNL.0000000000004313
Portaccio E, Annovazzi P, Ghezzi A, Zaffaroni M, Moiola L, Martinelli V, Lanzillo R, Brescia Morra V, Rinaldi F, Gallo P, Tortorella C, Paolicelli D, Pozzilli C, De Giglio L, Cavalla P, Cocco E, Marrosu MG, Patti F, Solaro C, Bellantonio P, Uccelli A, Laroni A, Pasto L, Giannini M, Trojano M, Comi G, Amato MP, Society MSSGotIN (2018) Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: fetal risks. Neurology 90(10):e823–e831. https://doi.org/10.1212/WNL.0000000000005067
Rog D, Oh J, Chambers C, Hellwig K, McCombe P, Otero S, Margolin DH, Daizadeh N, Compston DAS (2017) Pregnancy Outcomes in patients with RRMS treated with Alemtuzumab from the clinical development program. Paper presented at the 7th Joint European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS), Paris, France, 25–28 October 2017
Leruez-Ville M, Foulon I, Pass R, Ville Y (2020) Cytomegalovirus infection during pregnancy: state of the science. Am J Obstet Gynecol. https://doi.org/10.1016/j.ajog.2020.02.018
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Cinziavaleria Russo received personal compensation from Sanofi Genzyme and Merck Serono. Roberta Lanzillo received personal compensation from Bayer, Novartis, Almirall, Sanofi Genzyme, Biogen, Merck Serono, and TEVA for public speaking, editorial work, and advisory boards. Francesco Saccà received personal compensation from Almirall, Argenx, Avexis, Biogen, Forward Pharma, Merk, Mylan, Novartis, Pomona, Roche, Sanofi, and Teva for public speaking, editorial work, and advisory boards. Marcello Moccia has received research grants from ECTRIMS-MAGNIMS, UK MS Society, and Merck; honoraria from Biogen, Merck, Novartis, and Roche; and consultant fees from Veterans Evaluation Services. Carotenuto Antonio has received salary from Federico II University of Naples, research grants from ALMIRALL, and honoraria form Novartis, Merk, Merck, and Biogen. Vincenzo Brescia Morra received personal compensation from Bayer, Novartis, Almirall, Sanofi Genzyme, Biogen, Merck Serono, and TEVA for public speaking, editorial work, and advisory boards.
Ethical approval and Informed consent
Written informed consent from each reported patient was collected.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Valeria, R.C., Roberta, L., Francesco, S. et al. Pregnancy outcomes in alemtuzumab treated women with multiple sclerosis: a case series. Neurol Sci 42, 3427–3430 (2021). https://doi.org/10.1007/s10072-020-04975-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10072-020-04975-5